DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

Similar documents
HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN

PPHP 2017 Formulary 2017 Step Therapy Criteria

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

HEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

**CRITERIA UNDER CMS REVIEW**

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Pharmacy Management Drug Policy

Step Therapy Requirements. Effective: 1/1/2019

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Step Therapy Medications

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

Drug Name (specify drug) Quantity Frequency Strength

Step Therapy Requirements. Effective: 05/01/2018

Step Therapy Requirements. Effective: 11/01/2018

ANTICONVULSANTS. Details

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Step Therapy Group. Atypical Antipsychotic Agents

Step Therapy Criteria

ACTEMRA (tocilizumab)

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

Carelirst.+.V Family of health care plans

ADHD STIMULANTS-S(SHC)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Drug Therapy Guidelines

2016 Step Therapy (ST) Criteria

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

DRAFT. Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Simponi / Simponi ARIA (golimumab)

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Biologics for Autoimmune Diseases

ALPHA GLUCOSIDASE INHIBITOR THERAPY

Ontario Public Drug Programs

Regulatory Status FDA approved indication: Kineret is an interleukin-1 receptor antagonist indicated for: (1)

Quarterly pharmacy formulary change notice

Step Therapy Criteria

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

Quarterly pharmacy formulary change notice

Step Therapy Criteria 2019

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

ALLERGIC CONJUNCTIVITIS AGENTS

Cimzia. Cimzia (certolizumab pegol) Description

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

Immune Modulating Drugs Prior Authorization Request Form

Cimzia. Cimzia (certolizumab pegol) Description

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

2018 Step Therapy (ST) Criteria

RHEUMATOID ARTHRITIS DRUGS

Actemra. Actemra (tocilizumab) Description

ANTIDIABETIC AGENTS - MISCELLANEOUS

Step Therapy Requirements

Orencia (abatacept) DRUG.00040

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTICONVULSANTS. Details

Transcription:

DIFICID DIFICID TABLET 200 MG ORAL Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 days supply of vancomycin in the past. Otherwise, Dificid requires a step therapy exception request indicating: (1) history of inadequate treatment response with Vancomycin, OR (2) history of adverse event with Vancomycin, OR (3) Vancomycin is contraindicated. 1

GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level 1 agent (LANTUS, LEVEMIR, TOUJEO, TRESIBA, OR VICTOZA). Otherwise, Xultophy requires a step therapy exception request indicating: (1) history of inadequate treatment response with step 1 agent, OR (2) history of adverse event with step 1 agent, OR (3) step 1 agent is contraindicated. 2

LIVALO LIVALO TABLET 1 MG ORAL LIVALO TABLET 2 MG ORAL LIVALO TABLET 4 MG ORAL Claim will pay automatically for Livalo if enrollee has a paid claim for at least a 1 days supply of atorvastatin, lovastatin, pravastatin, or simvastatin in the past. Otherwise Livalo requires a step therapy exception request indicating: (1) history of inadequate treatment response with atorvvastatin, lovastatin, pravastatin, or simvastatin OR (2) history of adverse event with atorvastatin, lovastatin, pravastatin, or simvastatin OR (3) atorvastatin, lovastatin, pravastatin, or simvastatin is contraindicated. 3

LONG ACTING FENTANYL fentanyl patch 72 hour 100 mcg/hr fentanyl patch 72 hour 12 mcg/hr fentanyl patch 72 hour 25 mcg/hr fentanyl patch 72 hour 37.5 mcg/hr fentanyl patch 72 hour 50 mcg/hr fentanyl patch 72 hour 62.5 mcg/hr fentanyl patch 72 hour 75 mcg/hr fentanyl patch 72 hour 87.5 mcg/hr Claim will pay automatically for Fentanyl patches if enrollee has paid claims history for at least 1 days supply of either Morphine ER or Methadone in the past. Otherwise, the drug requires a step therapy exception request indicating any ONE of the following: (1) history of inadequate treatment response with Morphine ER or Methadone OR (2) history of adverse event with Morphine ER or methadone, OR (3) Morphine ER or Methadone are contraindicated. 4

MYRBETRIQ MYRBETRIQ TABLET EXTENDED RELEASE 24 HOUR 25 MG ORAL MYRBETRIQ TABLET EXTENDED RELEASE 24 HOUR 50 MG ORAL Claim will pay automatically for Myrbetriq if enrollee has a paid claim for at least a 1 days supply of any formulary urinary anticholinergic in the past. Otherwise, Myrbetriq requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary urinary anticholinergic, OR (2) history of adverse event with formulary urinary anticholinergic, OR (3) formulary urinary anticholinergic is contraindicated. 5

PROLIA PROLIA SOLUTION 60 MG/ML Patient needs to have a paid claim for one Step 1 drug (alendronate, ibandronate, pamidronate, or zolendronic acid) prior to filling a Prolia. For osteoporosis prophylaxis in men at high risk for bone fractures after receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women at high risk for bone fractures after receiving adjuvant aromatase inhibitor therapy for breast cancer, Prolia will be approved. 6

RHEUMATOID ARTHRITIS ACTEMRA SOLUTION 200 MG/10ML INTRAVENOUS ACTEMRA SOLUTION 400 MG/20ML INTRAVENOUS ACTEMRA SOLUTION 80 MG/4ML INTRAVENOUS ACTEMRA SOLUTION PREFILLED SYRINGE 162 MG/0.9ML CIMZIA KIT 2 X 200 MG CIMZIA PREFILLED KIT 2 X 200 MG/ML COSENTYX 300 DOSE SOLUTION PREFILLED SYRINGE 150 MG/ML COSENTYX SENSOREADY 300 DOSE SOLUTION AUTO-INJECTOR 150 MG/ML KINERET SOLUTION PREFILLED SYRINGE 100 MG/0.67ML ORENCIA CLICKJECT SOLUTION AUTO-INJECTOR 125 MG/ML ORENCIA SOLUTION PREFILLED SYRINGE 125 MG/ML ORENCIA SOLUTION PREFILLED SYRINGE 50 MG/0.4ML ORENCIA SOLUTION PREFILLED SYRINGE 87.5 MG/0.7ML ORENCIA SOLUTION RECONSTITUTED 250 MG INTRAVENOUS SIMPONI ARIA SOLUTION 50 MG/4ML INTRAVENOUS SIMPONI SOLUTION AUTO- INJECTOR 100 MG/ML SIMPONI SOLUTION AUTO- INJECTOR 50 MG/0.5ML SIMPONI SOLUTION PREFILLED SYRINGE 100 MG/ML SIMPONI SOLUTION PREFILLED SYRINGE 50 MG/0.5ML STELARA SOLUTION 45 MG/0.5ML STELARA SOLUTION PREFILLED SYRINGE 45 MG/0.5ML STELARA SOLUTION PREFILLED SYRINGE 90 MG/ML XELJANZ TABLET 5 MG ORAL 7

Claim will pay automatically for Actemra, Cimzia, Kineret, Orencia, Simponi, Stelara, Cosentyx or Xeljanz if enrollee has a paid claim for at least a 1 days supply of Enbrel AND Humira in the past. Enrollee does NOT need history of Humira prior to Actemra, Cimzia, Kineret, Orencia, Simponi, Stelara, Cosentyx or Xeljanz if diagnosed with Polyarticular Juvenile Idiopathic Arthritis (PJIA). Enrollee does NOT need history of Enbrel prior to Actemra, Cimzia, Kineret, Orencia, Simponi, Stelara, Cosentyx or Xeljanz if disgnosed with Crohns Disease (CD), Ulcerative Colitis (UC), Juvenile Idiopathic arthritis (JIA) or Systemic Juvenile Idiopathic arthritis (SJIA). Otherwise, Actemra, Cimzia, Kineret, Orencia, Simponi, Stelara, Cosentyx or Xeljanz requires a step therapy exception request indicating (1) history of inadequate treatment response with Enbrel AND Humira, OR (2) history of adverse event with Enbrel AND Humira, OR (3) Enbrel AND Humira is contraindicated. For diagnosis cryopyrin-associated periodic syndromes, Kineret will be approved. For diagnosis of Giant Cell Arteritis, Actemra will be approved. 8

TRINTELLIX TRINTELLIX TABLET 10 MG ORAL TRINTELLIX TABLET 20 MG ORAL TRINTELLIX TABLET 5 MG ORAL Claim will pay automatically for trintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past. Otherwise, trintellix requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants, OR (2) history of adverse event with any 2 generic formulary antidepressantss, OR (3) any 2 generic formulary antidepressants are contraindicated. 9

UCERIS UCERIS FOAM 2 MG/ACT RECTAL UCERIS TABLET EXTENDED RELEASE 24 HOUR 9 MG ORAL Claim will pay automatically for Uceris if enrollee has a paid claim for at least a 1 days supply of any formulary corticosteroid used to treat ulcerative colitis in the past. Otherwise, Uceris requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with formulary corticosteroid used to treat ulcerative colitis, OR (3) formulary corticosteroid used to treat ulcerative colitis is contraindicated. 10

ULORIC ULORIC TABLET 40 MG ORAL ULORIC TABLET 80 MG ORAL Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 1 days supply of Allopurinol in the past. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated. 11

VRAYLAR VRAYLAR CAPSULE 1.5 MG ORAL VRAYLAR CAPSULE 3 MG ORAL VRAYLAR CAPSULE 4.5 MG ORAL VRAYLAR CAPSULE 6 MG ORAL VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL Claim will pay automatically for VRAYLAR if enrollee has a paid claim for at least a 1 days supply of ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE OR LATUDA in the past. Otherwise, Vraylar requires a step therapy exception request indicating any ONE of criteria 1,2,3, OR 4: (1) history of inadequate treatment response with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE, or LATUDA OR (2) history of adverse event with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE, or LATUDA OR (3) ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE or LATUDA are contraindicated. OR (4) FOR Diagnosis OF MANIC EPIPISODES ASSOCIATED WTIH BIPOLAR DISORDER, THE COVERAGE DETERMINATION WILL BE APPROVED WITHOUT REQUIREMENT OF CONTRAINDICATION TO LATUDA. 12

XTANDI XTANDI CAPSULE 40 MG ORAL Claim will pay automatically for Xtandi if enrollee has a paid claim for at least a 1 days supply of Zytiga in the past. Otherwise, Xtandi requires a step therapy exception request indicating: (1) history of inadequate treatment response with Zytiga, OR (2) history of adverse event with Zytiga, OR (3)Zytiga is contraindicated. 13

Alphabetical Listing A ACTEMRA SOLUTION 200 MG/10ML INTRAVENOUS... 7, 8 ACTEMRA SOLUTION 400 MG/20ML INTRAVENOUS... 7, 8 ACTEMRA SOLUTION 80 MG/4ML INTRAVENOUS... 7, 8 ACTEMRA SOLUTION PREFILLED SYRINGE 162 MG/0.9ML... 7, 8 C CIMZIA KIT 2 X 200 MG... 7, 8 CIMZIA PREFILLED KIT 2 X 200 MG/ML... 7, 8 COSENTYX 300 DOSE SOLUTION PREFILLED SYRINGE 150 MG/ML... 7, 8 COSENTYX SENSOREADY 300 DOSE SOLUTION AUTO-INJECTOR 150 MG/ML... 7, 8 D DIFICID TABLET 200 MG ORAL... 1 F fentanyl patch 72 hour 100 mcg/hr fentanyl patch 72 hour 12 mcg/hr fentanyl patch 72 hour 25 mcg/hr fentanyl patch 72 hour 37.5 mcg/hr fentanyl patch 72 hour 50 mcg/hr fentanyl patch 72 hour 62.5 mcg/hr fentanyl patch 72 hour 75 mcg/hr fentanyl patch 72 hour 87.5 mcg/hr K KINERET SOLUTION PREFILLED SYRINGE 100 MG/0.67ML... 7, 8 L LIVALO TABLET 1 MG ORAL... 3 LIVALO TABLET 2 MG ORAL... 3 LIVALO TABLET 4 MG ORAL... 3 M MYRBETRIQ TABLET EXTENDED RELEASE 24 HOUR 25 MG ORAL... 5 MYRBETRIQ TABLET EXTENDED RELEASE 24 HOUR 50 MG ORAL... 5 O ORENCIA CLICKJECT SOLUTION AUTO-INJECTOR 125 MG/ML... 7, 8 ORENCIA SOLUTION PREFILLED SYRINGE 125 MG/ML... 7, 8 ORENCIA SOLUTION PREFILLED SYRINGE 50 MG/0.4ML... 7, 8 ORENCIA SOLUTION PREFILLED SYRINGE 87.5 MG/0.7ML... 7, 8 ORENCIA SOLUTION RECONSTITUTED 250 MG INTRAVENOUS... 7, 8 P PROLIA SOLUTION 60 MG/ML... 6 S SIMPONI ARIA SOLUTION 50 MG/4ML INTRAVENOUS... 7, 8 SIMPONI SOLUTION AUTO-INJECTOR 100 MG/ML... 7, 8 SIMPONI SOLUTION AUTO-INJECTOR 50 MG/0.5ML... 7, 8 SIMPONI SOLUTION PREFILLED SYRINGE 100 MG/ML... 7, 8 SIMPONI SOLUTION PREFILLED SYRINGE 50 MG/0.5ML... 7, 8 STELARA SOLUTION 45 MG/0.5ML... 7, 8 14

STELARA SOLUTION PREFILLED SYRINGE 45 MG/0.5ML... 7, 8 STELARA SOLUTION PREFILLED SYRINGE 90 MG/ML... 7, 8 T TRINTELLIX TABLET 10 MG ORAL... 9 TRINTELLIX TABLET 20 MG ORAL... 9 TRINTELLIX TABLET 5 MG ORAL... 9 U UCERIS FOAM 2 MG/ACT RECTAL... 10 UCERIS TABLET EXTENDED RELEASE 24 HOUR 9 MG ORAL... 10 ULORIC TABLET 40 MG ORAL... 11 ULORIC TABLET 80 MG ORAL... 11 V VRAYLAR CAPSULE 1.5 MG ORAL... 12 VRAYLAR CAPSULE 3 MG ORAL... 12 VRAYLAR CAPSULE 4.5 MG ORAL... 12 VRAYLAR CAPSULE 6 MG ORAL... 12 VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL... 12 X XELJANZ TABLET 5 MG ORAL... 7, 8 XTANDI CAPSULE 40 MG ORAL... 13 XULTOPHY SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML... 2 15